Review Article
Interleukin-6: a villain in the drama of pancreatic cancer development and progression

https://doi.org/10.1016/S1499-3872(14)60259-9Get rights and content

Background

Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a poor prognosis and little treatment options. The development and progression of the disease is fostered by inflammatory cells and cytokines. One of these cytokines is interleukin-6 (IL-6), which plays an important role in a wide range of biologic activities.

Data Sources

A systematic search of PubMed was performed to identify relevant studies using key words such as interleukin-6, inflammatory cytokines, inflammation and pancreatic cancer or PDAC. Articles related to IL-6 and pancreatic cancer were systematically reviewed.

Results

IL-6 is elevated in the serum of pancreatic cancer patients and correlates with cachexia, advanced tumor stage and poor survival. Its expression is enhanced by hypoxia and proteins involved in pancreatic cancer development like Kras, mesothelin or ZIP4. IL-6 in turn contributes to the generation of a pro-tumorigenic microenvironment and is probably involved in angiogenesis and metastasis. In experimental mouse models of PDAC, IL-6 was important for the development and progression of precursor lesions.

Conclusion

IL-6 emerges as a key player in pancreatic cancer development and progression, and hence should be considered as a new therapeutic target.

References (97)

  • JR Hecht et al.

    EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study

    Gastrointest Endosc

    (2012)
  • Y Guo et al.

    Interleukin-6 signaling pathway in targeted therapy for cancer

    Cancer Treat Rev

    (2012)
  • X Yao et al.

    Targeting interleukin-6 in inflammatory autoimmune diseases and cancers

    Pharmacol Ther

    (2014)
  • J Scheller et al.

    Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities

    Semin Immunol

    (2014)
  • JF Bromberg et al.

    Stat3 as an oncogene

    Cell

    (1999)
  • DT Fisher et al.

    The two faces of IL-6 in the tumor microenvironment

    Semin Immunol

    (2014)
  • T Ara et al.

    Interleukin-6 in bone metastasis and cancer progression

    Eur J Cancer

    (2010)
  • M Lesina et al.

    Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer

    Cancer Cell

    (2011)
  • KC Fearon et al.

    Cachexia in pancreatic cancer: new treatment options and measures of success

    HPB (Oxford)

    (2010)
  • KC Fearon et al.

    Cancer cachexia: mediators, signaling, and metabolic pathways

    Cell Metab

    (2012)
  • A Fukuda et al.

    Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression

    Cancer Cell

    (2011)
  • MC Bibby

    Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages

    Eur J Cancer

    (2004)
  • J Sodenkamp et al.

    Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis

    Immunobiology

    (2012)
  • American Cancer Society

    Cancer facts & figures – 2013, 2013 [cited 2014 Apr 10] 2013 Jan 2

  • A Maitra et al.

    Pancreatic cancer

    Annu Rev Pathol

    (2008)
  • M Hidalgo

    Pancreatic cancer

    N Engl J Med

    (2010)
  • A Kleger et al.

    Smarter drugs emerging in pancreatic cancer therapy

    Ann Oncol

    (2014 Mar 14)
  • A Neesse et al.

    Stromal biology and therapy in pancreatic cancer

    Gut

    (2011)
  • C Feig et al.

    The pancreas cancer microenvironment

    Clin Cancer Res

    (2012)
  • S Hinz et al.

    Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer

    Cancer Res

    (2007)
  • A Evans et al.

    The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion

    Front Physiol

    (2012)
  • CW Steele et al.

    Exploiting inflammation for therapeutic gain in pancreatic cancer

    Br J Cancer

    (2013)
  • MA Collins et al.

    Kras as a key oncogene and therapeutic target in pancreatic cancer

    Front Physiol

    (2014)
  • R Reznik et al.

    Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma

    Front Physiol

    (2014)
  • JH Egberts et al.

    Superiority of extended neoadjuvant chemotherapy with gemcitabine in pancreatic cancer: a comparative analysis in a clinically adapted orthotopic xenotransplantation model in SCID beige mice

    Cancer Biol Ther

    (2007)
  • AA Rucki et al.

    Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies

    World J Gastroenterol

    (2014)
  • AB Lowenfels et al.

    Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group

    N Engl J Med

    (1993)
  • N Momi et al.

    Discovering the route from inflammation to pancreatic cancer

    Minerva Gastroenterol Dietol

    (2012)
  • SY Gidekel Friedlander et al.

    Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras

    Cancer Cell

    (2009)
  • H Funahashi et al.

    Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor

    Cancer Res

    (2007)
  • BF El-Rayes et al.

    A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

    Invest New Drugs

    (2005)
  • Z Zhang et al.

    NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review)

    Int J Oncol

    (2006)
  • JH Egberts et al.

    Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis

    Cancer Res

    (2008)
  • C Wu et al.

    Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease

    Pancreas

    (2013)
  • W Schmiegel et al.

    Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer

    Proc Natl Acad Sci U S A

    (1997)
  • M Li et al.

    Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer

    Cancer Sci

    (2008)
  • Y Matsuo et al.

    CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer

    Int J Cancer

    (2009)
  • S Rose-John

    IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6

    Int J Biol Sci

    (2012)
  • Cited by (87)

    View all citing articles on Scopus

    Published online May 14, 2014.

    View full text